Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio ViewXTAE:BIOV +0.12%41 OCF Margin % is 1.79% as of Dec. 2025, which is 1% above its 10-year median of 1.77. GuruFocus rates XTAE:BIOV with a GF Score™ of 41/100 and a GF Value™ of ₪1.71 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Bio View ranks worse than 73.55% on this metric.
The historical rank and industry rank for Bio View's OCF Margin % or its related term are showing as below:
XTAE:BIOV'
s OCF Margin % Range Over the Past 10 Years
Min: -15.34 Med: 1.77 Max: 11.2
Current: -15.34
During the past 13 years, the highest OCF Margin % of Bio View was 11.20%. The lowest was -15.34%. And the median was 1.77%.
XTAE:BIOV's OCF Margin % is ranked worse than 73.55% of 813
companies
in the Medical Devices & Instruments industry
Industry Median: 6.43
vs XTAE:BIOV: -15.34
The historical data trend for Bio View's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:BIOV vs ABT, SYK, MDT: OCF Margin % Comparison
For the Medical Devices subindustry, Bio View's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio View OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio View's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Bio View's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio View (XTAE:BIOV) has a OCF Margin % of 1.79% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bio View and its competitors. This is near median its historical median of 1.77. According to the industry distribution chart, Bio View ranks #598 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 73.6%.
Is Bio View's OCF Margin % too high?
Bio View's current OCF Margin % of 1.79% is near median its 10-year median of 1.77. The Medical Devices & Instruments industry median OCF Margin % is 6.43. Bio View's value of 1.79% is 72.2% below this industry median. Based on the distribution chart, Bio View ranks #598 out of 813 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bio View has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio View's OCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bio View ranks #598 out of 813 companies for OCF Margin %. This places Bio View in the lower half of its industry. The industry median OCF Margin % is 6.43. Bio View's value of 1.79% is 72.2% below this benchmark. While the company's 10-year median is 1.77 vs. the industry median of 6.43, Bio View has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 6.43, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio View's current OCF Margin % of 1.79% is 72.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bio View and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 6.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio View's current OCF Margin % is 1.79%, which is near median its own 10-year median of 1.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio View stock overvalued right now?
Based on GuruFocus' analysis, Bio View (XTAE:BIOV) is currently considered Possible Value Trap. The stock's GF Value™ is ₪1.71, compared to a current price of ₪0.82 — trading 52.3% below its estimated fair value. The current OCF Margin % is 1.79%, which is near median its 10-year median of 1.77 and 72.2% below the Medical Devices & Instruments industry median of 6.43. Bio View's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Bio View (XTAE:BIOV), the current OCF Margin % is 1.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio View (XTAE:BIOV) Overvalued in 2026?
Based on GuruFocus' analysis, Bio View stock appears to be undervalued.
The current stock price of ₪0.82 is trading 52.3% below its estimated GF Value™ of ₪1.71.
GuruFocus considers Bio View to be Possible Value Trap.
Key valuation signals for XTAE:BIOV:
OCF Margin %: 1.79% (near median its 10-year median of 1.77)
GF Value™: ₪1.71 vs. price of ₪0.82 (52.3% below fair value)
Industry Position: 72.2% below the Medical Devices & Instruments median (#598 of 813)
No single metric tells the full story. See the XTAE:BIOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.
41GF Score
Get the complete analysis for XTAE:BIOV
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:BIOV has been successfully added to your 
